Comparing diabetes prediction based on metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease: the ELSA-Brasil study
Authors:
- Gabriela Wünsch LopesGLGabriela Wünsch Lopes
- Scheine Leite CanhadaSCScheine Leite Canhada
- Rodrigo Citton Padilha dos ReisRRRodrigo Citton Padilha dos Reis
- Maria de Fátima Haueisen Sander DinizMDMaria de Fátima Haueisen Sander Diniz
- Alessandra Carvalho GoulartAGAlessandra Carvalho Goulart
- Luciana Costa FariaLFLuciana Costa Faria
- Rosane Harter GriepRGRosane Harter Griep
- Hugo PerazzoHPHugo Perazzo
- Bruce Bartholow DuncanBDBruce Bartholow Duncan
- Maria Inês SchmidtMSMaria Inês Schmidt
Open Access
- 1 January 2024
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Cadernos de Saude Publica
- Vol. 40 (11) , e00009924
Abstract
We aimed to compare nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) definitions concerning diabetes prediction in a large sample of Brazilian adults. As a secondary objective, we compared associations between NAFLD/MASLD and diabetes across self-declared race/skin color groups. The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) is a prospective cohort study of Brazilian civil servants (35-74 years) enrolled from 2008 to 2010 and followed up from 2012-2014 and 2017-2019. We ascertained type 2 diabetes mellitus at baseline as well as follow-up visits based on self-reported diagnosis, medication use, and glycemic tests (fasting and 2h post-OGTT glucose and HbA1c). We excluded individuals with heavy alcohol consumption or self-reported cirrhosis/hepatitis. We analyzed 7,073 subjects. NAFLD was defined by ultrasound-based steatosis. Participants with steatosis and at least one cardiometabolic factor were considered as having MASLD. Cox proportional hazards models were performed to evaluate the association between NAFLD/MASLD and the incidence of type 2 diabetes mellitus. At baseline, 33.9% of individuals presented NAFLD and 32.5% presented MASLD. Over 9.4 years of follow-up, the relative increase in the incidence of diabetes was 78% for NAFLD (HR = 1.78; 95%CI: 1.58-2.01) and 88% for MASLD (HR = 1.88; 95%CI: 1.67-2.12). Associations did not differ significantly among race/skin color groups (p for interaction = 0.10 for MASLD and 0.08 for NAFLD). In this large cohort of middle-aged and older Brazilian adults, the relative incidence of diabetes was similar for NAFLD and MASLD definitions, with similar associations in all ethnic groups.Keywords
This publication has 37 references indexed in Scilit:
- Racial difference in the association between non-alcoholic fatty liver disease and incident type 2 diabetes: findings from the CARDIA studyDiabetologia, 2023
- Trends and predictions of malnutrition and obesity in 204 countries and territories: an analysis of the Global Burden of Disease Study 2019eClinicalMedicine, 2023
- Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019Clinics and Research in Hepatology and Gastroenterology, 2022
- Racial discrimination is associated with greater arterial stiffness and carotid intima-media thickness: the ELSA-Brasil studyAnnals of Epidemiology, 2022
- Social Determinants of Health, Race, and Diabetes Population Health Improvement: Black/African Americans as a Population ExemplarCurrent Diabetes Reports, 2022
- Diabetes Complications in Racial and Ethnic Minority Populations in the USACurrent Diabetes Reports, 2021
- Prevalence of Diabetes by Race and Ethnicity in the United States, 2011-2016JAMA, 2019
- Ethnic Disparities in Adiposity: Focus on Non-alcoholic Fatty Liver Disease, Visceral, and Generalized ObesityCurrent Obesity Reports, 2019
- Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2018
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver diseaseJournal of Hepatology, 2016